Key Takeaway
The Global FKRP Registry is one of the most important public infrastructure records in this space because it supports natural-history work, care standards, and future trial recruitment.
Trial and Study Record
Global FKRP Registry
International FKRP patient-registry record designed to characterize the population, support standards of care work, and help identify participants for future studies.
RegistryRegistryNatural HistoryFamilies
Why this record matters
- Registry participation is not treatment, but it matters because it helps define the global FKRP population and can support future study planning.
- The record explicitly links registry data collection to clinical-trial facilitation and standards-of-care development.
- This is also a practical bridge between paper summaries and active study tracking on the site.
Eligibility and participation notes
- Open to people with a confirmed FKRP-related condition based on genetic testing.
- Includes child, adult, and older adult participants and does not list exclusion criteria for registry enrollment.
- Collects patient-reported and clinician-reported information including respiratory and cardiac measures, genetics, quality of life, and pain.
Limits and cautions
- Registry data quality depends on ongoing updates and completeness of participant and clinician reporting.
- A recruiting registry does not by itself answer treatment-effect questions.
- Public record language should not be read as a guarantee of trial availability for any individual participant.
Primary Sources
Direct links for verification
Primary source used for the structured study summary on this page.
Related Content
Related routes inside the site
Study Record
Study of BBP-418 in Patients With LGMD2I
Phase 2 open-label ribitol study in FKRP-related LGMD2I/LGMDR9 that provides the main early clinical development context for the BBP-418 program.
Guide
For Researchers
This page is the research-oriented route into the FKRP site. It is designed to support literature capture, terminology alignment, and use of the paper and study libraries without assuming the user wants to start inside a database index.
Study Record
BBP-418 (Ribitol) FORTIFY Trial in LGMD2I/LGMDR9
Phase 3 randomized ribitol trial in FKRP-related LGMD2I/LGMDR9 and the most advanced current interventional program identified in this FKRP research sweep.